TrialsgrambetaRCTs are beautiful

MAGPIE

2002

Magnesium Sulphate for Prevention of Eclampsia trial

In 10,141 women with pre-eclampsia before delivery or shortly afterwards, magnesium sulphate halved the risk of eclamptic convulsions compared with placebo, without reducing perinatal death.

Result

Eclampsia; and, for women randomised before delivery, death of the baby
Absolute difference
1.1 points
NNT
91
Effect estimate

lower risk5895% CI 40-71

Absolute difference and NNT are derived from the event rates.

Also reported: No clear difference in death of the baby (12.7 % vs 12.4 %). Side effects, mainly flushing, in 24 % vs 5 %.

Original publication
Subtopic
Eclampsia prevention
Design
International, placebo-controlled RCT in 33 countries
Relevance
Practice-defining: a trial the field needs to know.
Source
Altman D, Carroli G, Duley L, et al. Lancet. 2002;359(9321):1877-1890.doi 10.1016/S0140-6736(02)08778-0

Discussion & critique

The absolute benefit is modest where baseline eclampsia rates are low, a quarter of treated women had side effects, and perinatal death was unchanged. But with 10,141 women across 33 countries it settled the question definitively: magnesium sulphate, not phenytoin or diazepam, is the anticonvulsant of choice in pre-eclampsia.